세계의 클로닝 및 돌연변이유발 시장 - 산업 규모, 점유율, 동향, 기회, 예측 : 유전자 유형별, 제품 유형별, 기술별, 용도별, 최종 사용자별, 지역별 경쟁(2020-2030년)
Cloning & Mutagenesis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Gene Type, By Product Type, By Technique, By Application, By End User, By Region and Competition, 2020-2030F
상품코드:1738283
리서치사:TechSci Research
발행일:2025년 05월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 클로닝 및 돌연변이유발 시장은 2024년에는 26억 7,000만 달러로 평가되었으며, 2030년에는 75억 8,000만 달러에 이르고, CAGR 18.99%를 나타낼 것으로 예측됩니다.
이 시장은 유전자 연구와 생식 연구 등 분야에서 클론 기술의 응용이 확대되고 있는 것이 큰 요인이 되어 급성장을 이루고 있습니다. 세계 증가는 시장 확대에 크게 기여할 것으로 예측됩니다. 유전자 치료의 장점과 조기 진단 툴에 대한 의식 증가와, 만성 질환 관리에 대한 헬스케어 지출 증가 또한 시장의 성장 궤도를 지지하고 있습니다.
The Global Cloning & Mutagenesis Market was valued at USD 2.67 billion in 2024 and is anticipated to reach USD 7.58 billion by 2030, growing at a CAGR of 18.99%. This market is witnessing rapid growth, largely fueled by expanding applications of cloning techniques in fields such as genetic and reproductive research. The increasing number of product launches involving cloning and mutagenesis kits, along with rising governmental investment in stem cell research for therapeutic development, is further driving demand. Additionally, the global rise in the aging population-more susceptible to chronic illnesses and metabolic disorders-is expected to significantly contribute to market expansion. Heightened awareness of gene therapy benefits and early diagnostic tools, combined with increased healthcare spending on chronic disease management, also supports the market's growth trajectory. Moreover, the global burden of diseases like head and neck cancer continues to drive demand for genetic engineering tools for advanced treatment solutions.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 2.67 Billion
Market Size 2030
USD 7.58 Billion
CAGR 2025-2030
18.99%
Fastest Growing Segment
Mutagenesis Kits
Largest Market
North America
Key Market Drivers
Rising Demand for Genetically Engineered Products in Biotechnology and Pharmaceuticals
The global demand for genetically engineered products is one of the major growth catalysts for the cloning and mutagenesis market. These technologies are vital in developing new drugs, gene therapies, vaccines, and synthetic biological products. Cloning and mutagenesis techniques allow scientists to manipulate genes for desired traits, making them indispensable in genetic research and biopharmaceutical manufacturing. Significant public investments reinforce this trend-for instance, the U.S. Department of Health and Human Services allocated over $2.5 billion to BARDA in 2023 to support advanced vaccine and therapeutic development, much of which relies on gene manipulation techniques. Similarly, under its Horizon Europe framework, the European Commission has earmarked over €1 billion for health innovation, focusing on gene-based solutions and personalized medicine.
Key Market Challenges
Ethical and Regulatory Concerns Around Genetic Manipulation
The ethical and regulatory landscape surrounding genetic engineering poses a major challenge for the cloning and mutagenesis market. Concerns about biosafety, environmental impact, and moral implications, especially in human applications like germline editing and embryonic cloning, have led to global scrutiny. While somatic cell gene editing is generally accepted, public and institutional opposition to germline modifications persists. Following incidents like the unauthorized editing of human embryos in 2018, regulatory bodies such as the WHO and UNESCO have called for stricter oversight. Regulatory inconsistencies between regions further complicate the market-while agencies like the FDA and EMA allow controlled gene therapy, other countries enforce bans on certain genetic techniques. The EU, for example, imposes rigorous regulations on GMOs, often delaying their approval. These regulatory and ethical hurdles not only slow innovation but also increase compliance costs, especially for companies operating in sensitive sectors like human therapeutics and agricultural biotechnology.
Key Market Trends
Integration of Artificial Intelligence in Genetic Engineering Workflows
The adoption of artificial intelligence in genetic research is a transformative trend in the cloning and mutagenesis market. AI and machine learning technologies are being increasingly utilized to automate gene synthesis, select optimal mutagenesis sites, design primers, and predict protein behavior after mutation. These tools help researchers conduct high-precision experiments more efficiently and cost-effectively. AI-driven analysis of large genomic datasets enables faster identification of gene targets and potential phenotypic outcomes, streamlining drug development and genetic research. Government support is also fostering this integration. For instance, the U.S. has prioritized AI in healthcare through the National Artificial Intelligence Initiative Act and allocated over $1.5 billion for related research in 2023. Similarly, Europe's Horizon Europe program promotes AI-based innovation in biotechnology. As AI systems become more advanced and widely adopted, their impact on genetic engineering is expected to enhance the reproducibility, speed, and accuracy of cloning and mutagenesis experiments across the pharmaceutical, agricultural, and research sectors.
Key Market Players
Agilent Technologies, Inc.
Eurofins Scientific SE
Sartorius AG
Collecta, Inc.
Codex DNA Inc.
Lonza Group AG
Charles River Laboratories International, Inc.
TransGene Biotech Co. Ltd.
Takara Bio, Inc.
Thermo Fisher Scientific Inc.
Report Scope:
In this report, the Global Cloning & Mutagenesis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Cloning & Mutagenesis Market, By Gene Type:
Standard
Complex
Cloning & Mutagenesis Market, By Product Type:
Cloning Kits
Mutagenesis Kits
Cloning & Mutagenesis Market, By Technique:
Topo PCR Cloning
Blunt End Cloning
Seamless Cloning
Site-Directed Mutagenesis
Cloning & Mutagenesis Market, By Application:
Gene Synthesis
Gene Expression
Gene Therapy
Vaccine Research
Others
Cloning & Mutagenesis Market, By End User:
Pharmaceutical & Biotechnology Companies
Academic & Research Institutions
Others
Cloning & Mutagenesis Market, By Region:
North America
United States
Mexico
Canada
Europe
France
Germany
United Kingdom
Italy
Spain
Asia-Pacific
China
India
South Korea
Japan
Australia
South America
Brazil
Argentina
Colombia
Middle East and Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Cloning & Mutagenesis Market.
Available Customizations:
Global Cloning & Mutagenesis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Cloning & Mutagenesis Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Gene Type (Standard, Complex)
5.2.2. By Product Type (Cloning Kits, Mutagenesis Kits)
5.2.3. By Technique (Topo PCR Cloning, Blunt End Cloning, Seamless Cloning, Site-Directed Mutagenesis, Others)
